[1]杨露露,崔勇,杨森.几种合成肽对系统性红斑狼疮治疗作用的研究进展[J].中国皮肤性病学杂志,2016,(12):1284-1286.[doi:10.13735/j.cjdv.1001-7089.201503083]
 YANG Lu-lu,CUI Yong,YANG Sen.The Progress in the Treatment of Systemic Lupus Erythematosus with Synthetic Peptides[J].The Chinese Journal of Dermatovenereology,2016,(12):1284-1286.[doi:10.13735/j.cjdv.1001-7089.201503083]
点击复制

几种合成肽对系统性红斑狼疮治疗作用的研究进展
分享到:

《中国皮肤性病学杂志》[ISSN:1001-7089/CN:61-1197/R]

卷:
期数:
2016年12期
页码:
1284-1286
栏目:
综述
出版日期:
2016-12-20

文章信息/Info

Title:
The Progress in the Treatment of Systemic Lupus Erythematosus with Synthetic Peptides
作者:
杨露露崔勇杨森
[通讯作者] 杨森,E-mail: yangsen@medmail.com.cn
Author(s):
YANG Lu-lu CUI Yong YANG Sen
Department of Dermatology and Venereology, the First Affiliated Hospital of Anhui Medical University, Hefei 230032, China
关键词:
合成肽 系统性红斑狼疮
Keywords:
Synthetic peptides Systemic lupus erythematosus
分类号:
R 593.24
DOI:
10.13735/j.cjdv.1001-7089.201503083
文献标志码:
B
摘要:
系统性红斑狼疮(SLE)是一种病因不明的慢性自身免疫性疾病,可导致多系统的损害。 本病目前治疗手段有限,多数药物作用机制为针对患者的免疫应答失衡。合成肽作为一种新型药 物,靶向作用于狼疮发病机制相关细胞表面的特定抗原,因此具有针对性强、副作用少的优点。 合成肽具有诱导免疫耐受的作用,并且可改善小鼠模型中该疾病的临床表现。本文对合成肽治疗 系统性红斑狼疮的临床前研究和作用机制作一综述。
Abstract:
Systemic lupus erythematosus(SLE)is a chronic autoimmune disease with unknown etiology, which can cause multi-organ damages.Therapeutic approaches are still limited although various immunomodulators are available to improve the imbalanced immune responses.However, synthetic peptides can serve as antigenic epitopes, targeting specific antigens on the surface of cells which are associated with the pathogenesis of SLE.Due to their high specificity, synthetic peptides exhibit fewer side effects.Synthetic peptide can induce immune tolerance and improve clinical symptoms of SLE in murine model.In this review we give an overview on the preclinical study of synthetic peptides in treating SLE and the underlying mechanisms.

参考文献/References:

[1] Ahlin E,Mathsson L,Eloranta ML,et al.Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE [J].Lupus,2012,21(6):586-595.
[2] Sthoeger Z,Sharabi A,Mozes E.Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus[J].J Autoimmun, 2014, 54(11): 60-71.
[3] Lourenco EV, Procaccini C, Ferrera F, et al.Modulation of p38 MAPK activity in regulatory T cells after tolerance with anti-DNA Ig peptide in(NZB x NZW)F1 lupus mice[J].J Immunol,2009,182(12):7415-7421.
[4] Dinesh R,Hahn BH,La Cava A,et al.Interferon-in-decible gene 202b controls CD+ T cell-mediated suppression in anti-DNA Ig petide-treated(NZB/NZW)F1 lupus mice[J].Genes Immun,2011,12(5):360-369.
[5] Skaggs BJ,Lourenco EV,Hahn BH.Oral administration of different forms of a tolerogenic peptide to define the preparations and doses that delay anti-DNA antibody production and nephritis and prolong survival in SLE-prone mice [J].Lupus,2011,20(9):912-920.
[6] Hahn BH,Anderson M,Le E,et al.Anti-DNA Ig peptides promote Treg cell activity in systemic lupus erythematosus patients[J].Arthritis Rheum,2008,58(8):2488-2497.
[7] Eggert M,Zettl UK,Neeck G.Autoantibodies in autoimmune diseases[J].Curr Pharm Des,2010,16(14):1634-1643.
[8] Doyle HA,Aswad DW,Mamula MJ.Autoimmunity to isomerized histone H2B in systemic lupus erythematosus[J].Autoimmunity,2013,46(1):6-13.
[9] Kang HK, Liu M, Datta SK.Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory Th17 cells[J].J Immunol, 2007,178(12):7849-7858.
[10] Kang HK,Chiang MY,Liu M,et al.The histone peptide H471–94 alone is more effective than a cocktail of peptide epitopes in controlling lupus: immunoregulatory mechanisms[J].J Clin Immunol,2011,31(3):379-394.
[11] Zhang L, Bertucci AM, Ramsey-Goldman R, et al.Major pathogenic steps in human lupus can be effectively suppressed by nucleosomal histone peptide epitope-induced regulatory immunity[J].Clin Immunol,2013,149(3):365-378.
[12] Briand JP, Schall N, Muller S.Generation of self-peptides to treatment systemic lupus Erythematosus[J].Methods Mol Bio,2014,1134(1064-3745):173-192.
[13] Muller S,Monneaux F,Schall N,et al.Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial [J].Arthritis Rheum,2008,58(12):3873-3883.
[14] Zimmer R,Scherbarth HR,Rillo OL,et al.Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial[J].Ann Rheum Dis,2013,72(11):1830-1835.
[15] Sthoeger ZM,Dayan M,Tcherniack A,et al.Modulation of autoreactive responses of peripheral blood lymphocytesof patients with systemic lupus erythematosus by peptides based on human and murine anti-DNA autoantibodies[J].Clin Exp Immunol,2003,131(2):385-392.
[16] Sharabi A,Luger D,Ben-David H,et al.The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model[J].J Immunol,2007,179(8):4979-4987.
[17] Parameswaran R,Ben David H,Sharabi A,et al.B-cell activating factor(BAFF)plays a role in the mechanism of action of a tolerogenic peptide that ameliorates lupus [J].Clin Immunol,2009,131(2):223-232.
[18] Telerman A,Lapter S,Sharabi A,et al.Induction of hippocampal neurogenesis by atolerogenic peptide that ameliorates lupus manifestations[J].J Neuroimmunol,2011,232(1-2):151-157.
[19] Sthoeger Z,Sharabi A,Dayan M,et al.The tolerogenic peptide hCDR1 down regulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients[J].Hum Immunol,2009,70(3):139-145.
[20] Sthoeger Z,Zinger H,Sharabi A,et al.The tolerogenic peptide, hCDR1, down- regulates the expression of interferon-α in murine and human systemic lupus erythematosus[J].PloS one,2013,8(3):e60394.
[21] Urowitz MB,Isenberg DA,Wallace DJ.Safety and efficacy of hCDR1(Edratide)in patients with active systemic lupus erythematosus: results of phase II study [J].Lupus Sci Med,2015,112(1):e000104.
[22] Ching KH,Burbelo PD,Tipton C,et al.Two major autoantibody clusters in systemic lupus erythematosus[J].PLoS One,2012,7(2):e32001.
[23] Riemekasten G,Langnickel D,Enghard P,et al.Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells[J].J Immunol,2004,173(9):5835-5842.

相似文献/References:

[1]周莹.系统性红斑狼疮并发股骨头坏死研究进展[J].中国皮肤性病学杂志,2017,(08):918.[doi:10.13735/j.cjdv.1001-7089.201606062]
 ZHOU Ying.Osteonecrosis of the Femoral Head in Patients with Systemic Lupus Erythematosus[J].The Chinese Journal of Dermatovenereology,2017,(12):918.[doi:10.13735/j.cjdv.1001-7089.201606062]
[2]李萌萌,陈涛,郭在培.肿瘤坏死因子相关弱凋亡诱导因子与相关皮肤病[J].中国皮肤性病学杂志,2013,(07):85.
 LI Meng-meng,CHEN Tao,GUO Zai-pei.TWEAK and Related Dermatoses[J].The Chinese Journal of Dermatovenereology,2013,(12):85.
[3]伊力努尔·哈力甫,梁俊琴,胡凤侠,等.免疫球蛋白受体ⅡB和ⅢA基因多态性与新疆维吾尔族SLE的遗传易感性分析[J].中国皮肤性病学杂志,2018,(12):1355.[doi:10.13735/j.cjdv.1001-7089.201804128]
 Yilinuer Halifu,LIANG Junqin,HU Fengxia,et al.Association of Polymorphisms in Immunoglobulin Receptor ⅡB and ⅢA Genes with Hereditary Susceptibility of Systemic Lupus Erythematosus in Xinjiang[J].The Chinese Journal of Dermatovenereology,2018,(12):1355.[doi:10.13735/j.cjdv.1001-7089.201804128]
[4]范思奇,曾平,秦刚,等.系统性红斑狼疮并发股骨头坏死危险因素的Meta分析[J].中国皮肤性病学杂志,2018,(12):1451.[doi:10.13735/j.cjdv.1001-7089.201801016]
 FAN Siqi,ZENG Ping,QIN Gang,et al.Meta-analysis of Risk Factors for Aseptic Femoral Head Necrosis in Patients with Systemic Lupus Erythematosus[J].The Chinese Journal of Dermatovenereology,2018,(12):1451.[doi:10.13735/j.cjdv.1001-7089.201801016]
[5]熊梦燎,李卉,周文明.皮肌炎和系统性红斑狼疮重叠综合征伴Degos样皮疹1例[J].中国皮肤性病学杂志,2020,(08):915.[doi:10.13735/j.cjdv.1001-7089.201909066]
 XIONG Mengliao,LI Hui,ZHOU Wenming.A Case of Degos-like Lesions in Systemic Lupus Erythematosus-Dermatomyositis Overlap Syndrome[J].The Chinese Journal of Dermatovenereology,2020,(12):915.[doi:10.13735/j.cjdv.1001-7089.201909066]

备注/Memo

备注/Memo:
安徽医科大学第一附属医院皮肤性病科/皮肤病研究所,安徽 合肥 230032
更新日期/Last Update: 2016-12-20